1. Clinical Use of Dexamethasone Implants in Resistant Macular Edema Secondary to Branch Retinal Vascular Occlusion Compared with Intravitreal Anti-Vascular Endothelial Growth Factor
- Author
-
Erdem Eris, Irfan Perente, Gurkan Erdogan, Zeynep Seymen, Mehmet Emin Sucu, Abdullah Ozkaya, Ali Demircan, Zeynep Alkin, Ahmet Demirok, and Ozgur Artunay
- Subjects
branch retinal vascular occlusion dexamethasone implant ,macular edema ,ranibizumab. ,Ophthalmology ,RE1-994 - Abstract
INTRODUCTION[|]Branch retinal vein occlusion (BRVO) is the second most common type of retinal vascular disorder. Both inflammation and increased vascular endothelial growth factor (VEGF) levels play important roles in the pathogenesis of macular edema (ME) secondary to BRVO. The aim of this study was to compare the efficacy of 0.7-mg intravitreal dexamethasone implants with continued anti-VEGF treatment in patients with ME secondary to BRVO who were poor responders to at least 6 previous anti-VEGF injections.[¤]METHODS[|]Patients exhibiting an insufficient response to at least 6 ranibizumab treatments and who subsequently underwent a dexamethasone implant were included Group 1. Patients who were at risk for cataract or glaucoma continued treatment with the same drug and were defined as Group 2. The best corrected visual acuity (BCVA) and central macular thickness (CMT) changes at month 2, 4, and 6 were measured.[¤]RESULTS[|] Ninety eyes were evaluated. In Group 1, the mean baseline BCVA of 0.71+-0.75 logarithm of the minimum angle of resolution (logMAR) improved to 0.53+-0.62 logMAR at month 2 (p
- Published
- 2019
- Full Text
- View/download PDF